Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0
暂无分享,去创建一个
A. Hatzakis | A. Worlock | H. Papachristou | S. Nair | Jacqueline Fortunko | Tracy Foote | HeeCheol Kim | Tashi L. Peling
[1] C. T. Nugent,et al. Aptima HIV-1 Quant Dx--A fully automated assay for both diagnosis and quantification of HIV-1. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[2] A. Speicher,et al. Comparative evaluation of the Aptima HIV-1 Quant Dx assay and COBAS TaqMan HIV-1 v2.0 assay using the Roche High Pure System for the quantification of HIV-1 RNA in plasma , 2016, Clinical chemistry and laboratory medicine.
[3] A. Caliendo,et al. Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples , 2016, Journal of Clinical Microbiology.
[4] J. Lundgren,et al. Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV‐positive persons , 2016, HIV medicine.
[5] Orna Mor,et al. Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load , 2015, Journal of Clinical Microbiology.
[6] A. Geretti,et al. Comparative performance of the new Aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[7] S. O'shea,et al. Performance of the Aptima® HIV-1 Quant Dx Assay on the Panther System , 2015 .
[8] C. Delaugerre,et al. Analytical sensitivity of three real-time PCR assays for measuring subtype B HIV-1 RNA. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[9] C. Stager,et al. COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test, Version 2.0 , 2012 .
[10] J. González-Alba,et al. [Quantification of HIV-1 viral load]. , 2011, Enfermedades infecciosas y microbiologia clinica.
[11] A. Hatzakis,et al. Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from Greece , 2011, Virology Journal.
[12] R. Schall,et al. Comparative Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2 Test Using the TaqMan 48 Analyzer and the Abbott RealTime HIV-1 Assay , 2010, Journal of Clinical Microbiology.
[13] M. Parker,et al. Performance of the Aptima HIV-1 RNA Qualitative Assay with 16- and 32-Member Specimen Pools , 2010, Journal of Clinical Microbiology.
[14] Gkikas Magiorkinis,et al. Increasing prevalence of HIV-1 subtype A in Greece: estimating epidemic history and origin. , 2007, The Journal of infectious diseases.
[15] F. Buonaguro,et al. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications , 2007, Journal of Virology.
[16] H. Niesters,et al. Multicenter Evaluation of the New Abbott RealTime Assays for Quantitative Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA , 2007, Journal of Clinical Microbiology.
[17] F. Wiesmann,et al. Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine , 2007, Clinical chemistry and laboratory medicine.
[18] A. Geretti,et al. Comparative Evaluation of the Performance of the Abbott Real-Time Human Immunodeficiency Virus Type 1 (HIV-1) Assay for Measurement of HIV-1 Plasma Viral Load following Automated Specimen Preparation , 2006, Journal of Clinical Microbiology.
[19] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[20] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .
[21] J. Kahn,et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.
[22] J. Goedert,et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.
[23] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[24] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[25] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. , 1996, The Journal of infectious diseases.
[26] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.